截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,00 ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 19 September 2025 Dear Non-registered holders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the websi ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear Registered Shareholders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the website of The Stock E ...

(incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司) (Stock Code 股份代號:950) 2025 INTERIM REPORT 中期報告 *For identification purpose only 僅 供 識 別 Interim Report 2025 中期報告 INTERIM FINANCIAL STATEMENTS The Directors present herewith the unaudited consolidated interim financial results (the "Interim Results") of the Group for the six months ended 30 June 2025, together with the comparative figures for the corresponding period in 2024. The Interim Results are unaudited, but have been reviewed b ...

李氏大药厂(00950)午后涨超27%，截至发稿，涨20.9%，报2.43港元，成交额4490.21万港元。 此外，中泰证券（600918）发布研报称，近年来双抗、ADC、小分子靶向药(TKI)、细胞治疗等创新疗 法推进肿瘤患者OS逐步延长，荷瘤患者的生存质量(QoL)是临床实践中关注的重要问题，过去较少药企 做针对性的药物开发。肿瘤恶病质和爆发性癌痛的"姑息治疗学科"关注的重要问题。该行指出，李氏大 药厂研发的芬太尼气溶胶吸入剂AZ003，可有效控制癌痛爆发痛，其2期临床结果于2024年ASCO发表。 该行认为该赛道未来将出现多个大单品，值得投资者重视。 消息面上，李氏大药厂此前发布中期业绩，该集团取得收益6.95亿港元，同比增加5.5%；主要由集团产 品组合稳健的销售表现所带动。2025年上半年的公司拥有人应占纯利为6718.5万港元，同比增加7.5%。 值得注意的是，李氏大药厂7月底公告称，旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单 抗新适应症上市申请已获得批准。 ...

此外，中泰证券发布研报称，近年来双抗、ADC、小分子靶向药（TKI）、细胞治疗等创新疗法推进肿 瘤患者OS逐步延长，荷瘤患者的生存质量（QoL）是临床实践中关注的重要问题，过去较少药企做针 对性的药物开发。肿瘤恶病质和爆发性癌痛的"姑息治疗学科"关注的重要问题。该行指出，李氏大药厂 研发的芬太尼气溶胶吸入剂AZ003，可有效控制癌痛爆发痛，其2期临床结果于2024年ASCO发表。该行 认为该赛道未来将出现多个大单品，值得投资者重视。 消息面上，李氏大药厂此前发布中期业绩，该集团取得收益6.95亿港元，同比增加5.5%；主要由集团产 品组合稳健的销售表现所带动。2025年上半年的公司拥有人应占纯利为6718.5万港元，同比增加7.5%。 值得注意的是，李氏大药厂7月底公告称，旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单 抗新适应症上市申请已获得批准。 智通财经APP获悉，李氏大药厂(00950)午后涨超27%，截至发稿，涨20.9%，报2.43港元，成交额 4490.21万港元。 ...

Core Insights - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.942 million shares at a price of HKD 1.8776 per share, totaling approximately HKD 5.5239 million [1] - After the reduction, GL Capital Management holds approximately 39.0995 million shares, representing a 6.64% ownership stake in the company [1] Related Parties - The transaction involves other related parties including Assicurazioni Generali SpA, Li Zhenfu, and Lion River I N.V. [1]

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.942 million shares at a price of HKD 1.8776 per share, totaling approximately HKD 5.5239 million [1] - After the reduction, GL Capital Management's remaining shareholding is approximately 39.0995 million shares, representing a holding percentage of 6.64% [1] - The transaction involves other related parties, including Assicurazioni Generali SpA, Li Zhenfu, and Lion River I N.V. [1]

致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 本月底法定/註冊股本總額： HKD 50,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | 李氏大藥廠控股有限公司 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 HKD | ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lee's Pharmaceutical Holdings Limited, which rose over 21% and is currently trading at 21 HKD, with a trading volume of 31.96 million HKD [1] - The company reported a mid-term revenue of 695 million HKD, reflecting a year-on-year increase of 5.5%, driven by strong sales performance of its product portfolio [1] - The net profit attributable to shareholders for the first half of 2025 was 67.185 million HKD, representing a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and improved operational strength [1] Group 2 - The company announced that its subsidiary, Zhaoke Pharmaceutical, received approval for a new indication for its anti-PD-L1 monoclonal antibody, Socazolimab, for use in combination chemotherapy as a first-line treatment for extensive-stage small cell lung cancer [1] - This approval marks the second indication for Socazolimab, following its initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]